Research
Guggenheim Initiates Bicara Therapeutics at Buy With $42 Price Target
Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $31.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$BCAX
